alexa
Reach Us +1-504-608-2390
Interferon-gamma Release Assay As A Diagnostic Biomarker For Tuberculosis Associated Uveitis | 7996
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Interferon-gamma release assay as a diagnostic biomarker for tuberculosis associated uveitis

International Conference & Exhibition on Clinical Research Dermatology, Ophthalmology & Cardiology

Marcus Ang

ScientificTracks Abstracts: JCEO

DOI: 10.4172/2155-9570.S1.01

Abstract
T-SPOT.TB is a new interferon-gamma release assay used to diagnose tuberculosis (TB). We studied the use of T-SPOT.TB as a diagnostic biomarker for TB-associated uveitis (TAU). A Prospective cohort study of 162 consecutive new patients with clinical ocular signs suggestive of TAU, seen over a 1 year period at a single tertiary center. All subjects underwent investigations to rule out underlying disease, including T-SPOT.TB and tuberculin skin test (TST). Twenty-one subjects with underlying disease and 3with interdeterminate T-SPOT.TB results were excluded. Those with T-SPOT.TB or TST positive results were referred to infectious diseases physician for evaluation. Anti-TB therapy (ATT) was prescribed if required. Patients? treatment response andrecurrence were monitored for 6 months post-completion of ATT, if given; or 1 year if no ATT was given. The mean age of study cohort (n=138) was 46.8?15.3 years. Majority were Chinese (n=80, 58.0%) and female (n=75, 54.3%). TST was more sensitive than TSPOT. TB (72.0% vs. 36.0%); but T-SPOT.TB was more specific (75.0% vs. 51.1%) for diagnosing TAU. Patients with either a T-SPOT.TB (1.44; 95% CI, 0.86-2.42) or TST (1.47; 95% CI, 1.12-1.94) positive result are more likely to have TAU. The accuracy of diagnosing TAU increases when both tests are used in combination (AUC = 0.665; 95% CI, 0.533- 0.795). Patients with both tests positive are 2.16 (95% CI, 1.23-3.80) times more likely to have TAU. Negative T-SPOT.TB or TST results do not exclude TAU (negative likelihood ratios <1.0). In conclusion, we found T-SPOT.TB is more specific but less sensitive than TST for diagnosing TAU. We recommend performing both tests to improve the accuracy in diagnosis.
Biography
Dr Marcus Ang is currently working at the Singapore National Eye Center, while pursuing a Masters in Clinical Investigation(Nat ional University of Singapore) for clinical research. He is involved in research under the Singapore Eye Research Institute to study infectious dis eases and immunology of the eye as well as novel ocular drug delivery technologies developed in conjunction with Nanyang Technological University (S ingapore). He has published in several journals such as Ophthalmology, American Journal of Ophthalmology, Eye, Cornea and Journal of Glaucoma.
Top